Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer’. The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatment.
The intervention under investigation is telisotuzumab vedotin, an experimental biological treatment administered via intravenous infusion every two weeks. It is being compared to docetaxel, a standard chemotherapy drug given every three weeks, to determine which is more effective in reducing disease activity and managing adverse events in NSCLC patients.
The study is designed as an open-label, randomized, and controlled trial with a parallel intervention model. Participants are randomly assigned to receive either telisotuzumab vedotin or docetaxel, with no masking involved, and the primary purpose is treatment.
The study began on March 25, 2022, and is currently recruiting participants. The last update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
This clinical update could influence AbbVie’s stock performance and investor sentiment, as positive results may enhance the company’s competitive position in the oncology market. Investors should monitor developments closely, considering the broader industry context and potential impacts on competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.